Criticism mounting over Zuellig Korea's excessive royalty payment to HK-based headquarters

With Zuellig Korea's recent announcement that for the past four years it had paid a total of 5.4 billion won to Hong-Kong-based Zuellig Pharma Holding Limited, known as the largest shareholder, in return for market and information service assistance, criticism is mounting over how such large royalty amount had gone paid even in the face of accumulated deficits of about 10 billion won since its ...